INM InMed Pharmaceuticals Inc. Common Shares
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 6
- List Date
- 2020-11-10
- CIK
- 0001728328
- Next Earnings
- 2026-11-05
- Headquarters
- Vancouver
- Homepage
- https://www.inmedpharma.com
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 20.63% | -11.03% | -16.74% | -7.72% | -35.83% | -1.79% | -8.75% |
| Feb | 0.72% | -20.49% | -29.26% | 14.33% | -4.23% | -22.73% | -10.28% |
| Mar | -25.17% | 6.33% | -11.48% | -11.00% | -27.37% | -21.35% | -15.01% |
| Apr | 9.68% | -1.69% | 9.59% | -29.53% | 43.04% | 7.41% | 6.42% |
| May | -15.23% | -26.67% | 14.53% | 12.64% | -19.42% | 119.73% | 14.26% |
| Jun | 2.58% | -36.86% | -29.81% | -13.04% | -4.97% | -0.64% | -13.79% |
| Jul | -10.18% | -17.02% | 21.74% | -30.13% | -21.36% | -5.16% | -10.35% |
| Aug | -20.79% | -39.75% | -20.29% | 98.38% | -7.11% | -7.53% | 0.48% |
| Sep | -25.21% | -13.81% | -14.75% | -24.57% | 1.39% | 3.03% | -12.32% |
| Oct | -10.29% | -53.29% | -28.33% | 19.77% | -15.32% | 17.78%* | -11.61% |
| Nov | 21.79% | -16.40% | -4.33% | -17.66% | -28.11% | -- | -8.94% |
| Dec | -19.63% | -24.91% | -7.56% | 9.47% | -16.54% | -- | -11.83% |
| Total | -59.48% | -95.67% | -75.92% | -26.84% | -81.60% | 48.95% | -48.43% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
INM Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Low volatility - stock moves less than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $40K | #6052 of 6285 | -44.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
INM Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
INM Insider Trading (Form 4)
Latest: 2026-10-20| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy (P) | +2,174 | $1.32 | $2.9K | EDGAR |
| 2026-10-15 | Daniel Schneeberger | 10%+ Owner | Buy (P) | +19,138 | $1.33 | $25.4K | EDGAR |
| 2026-10-08 | Daniel Schneeberger | 10%+ Owner | Buy (P) | +21,806 | $1.33 | $29.0K | EDGAR |
| 2026-10-05 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy (P) | +85,840 | $1.33 | $114.2K | EDGAR |
| 2026-09-16 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy (P) | +182,202 | $1.30 | $236.2K | EDGAR |
| 2026-07-17 | Daniel Schneeberger | 10%+ Owner | Buy (P) | +2,000 | $1.55 | $3.1K | EDGAR |
| 2026-07-16 | Vivo Opportunity Cayman, LLC | 10%+ Owner | Buy (P) | +82,184 | $1.55 | $127.4K | EDGAR |
| 2026-07-02 | Vivo Opportunity, LLC | 10%+ Owner | Buy (P) | +26,204 | $1.55 | $40.6K | EDGAR |
| 2026-06-10 | Vivo Opportunity Cayman Fund, L.P. | 10%+ Owner | Buy (P) | +996,908 | $1.57 | $1.57M | EDGAR |
| 2026-05-21 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy (P) | +937,102 | $1.54 | $1.44M | EDGAR |
| 2025-12-19 | Shane Aaron Johnson | Sr VP & General Manager | Grant (A) | +8,500 opt | — | EDGAR | |
| 2025-12-19 | Netta Jagpal | Chief Financial Officer | Grant (A) | +18,000 opt | — | EDGAR | |
| 2025-12-19 | Eric A Adams | President & CEO | Grant (A) | +35,000 opt | — | EDGAR | |
| 2025-12-19 | Michael Woudenberg | Chief Operating Officer | Grant (A) | +18,000 opt | — | EDGAR | |
| 2025-12-19 | Nicole Lemerond | Director | Grant (A) | +1,750 opt | — | EDGAR |
INM Insider Holdings
8 insiders · @ $1.59| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | ADAR1 Capital Management, LLC | 10%+ Owner | 955,494 | $1.52M | $1.80M | 4 | 2026-10-20 |
| 2 | Daniel Schneeberger | 10%+ Owner | 954,509 | $1.52M | $57.5K | 3 | 2026-10-15 |
| 3 | Vivo Opportunity Cayman, LLC | 10%+ Owner | 729,277 | $1.16M | $127.4K | 1 | 2026-07-16 |
| 4 | Vivo Opportunity, LLC | 10%+ Owner | 724,395 | $1.15M | $40.6K | 1 | 2026-07-02 |
| 5 | Vivo Opportunity Cayman Fund, L.P. | 10%+ Owner | 638,960 | $1.02M | $1.57M | 1 | 2026-06-10 |
| 6 | Eric A Adams | President & CEO | 2,198 | $3.5K | $70.1K | 19 | 2025-12-19 |
| 7 | Andrew Hull | Director | 1,913 | $3.0K | $14.6K | 11 | 2025-12-19 |
| 8 | Shane Aaron Johnson | Sr VP & General Manager | 609 | $968 | $28.3K | 9 | 2025-12-19 |
INM Board & Officers
As of SEC filings through Oct 20, 2026Directors 5
- Andrew Hull · since Nov 12, 2020
- Eric A Adams · since Nov 12, 2020
- Nicole Lemerond · since Aug 8, 2022
- Neil A Klompas · since Oct 9, 2024
- John Steven Bathery · since Oct 14, 2025
Officers 5
- Eric A Adams · President & CEO · since Nov 12, 2020
- Netta Jagpal · Chief Financial Officer · since Feb 20, 2024
- Michael Woudenberg · Chief Operating Officer · listed since Nov 2022
- Eric C Hsu · Sr. VP, Pre-Clinical Res/Dev · since Nov 12, 2020
- Shane Aaron Johnson · Sr VP & General Manager · listed since Nov 2022
10% owners 6
- ADAR1 Capital Management, LLC (entity) · since May 19, 2026
- Daniel Schneeberger · since May 19, 2026
- Vivo Opportunity Cayman Fund, L.P. (entity) · since May 19, 2026
- Vivo Opportunity Cayman, LLC (entity) · since May 19, 2026
- Vivo Opportunity Fund Holdings, L.P. (entity) · since May 19, 2026
- Vivo Opportunity, LLC (entity) · since May 19, 2026
Changes in the last 10 years (36)
| May 19, 2026 | Vivo Opportunity, LLC became a 10% owner |
| May 19, 2026 | Vivo Opportunity Fund Holdings, L.P. became a 10% owner |
| May 19, 2026 | Vivo Opportunity Cayman, LLC became a 10% owner |
| May 19, 2026 | Vivo Opportunity Cayman Fund, L.P. became a 10% owner |
| May 19, 2026 | Daniel Schneeberger became a 10% owner |
| May 19, 2026 | ADAR1 Capital Management, LLC became a 10% owner |
| Oct 15, 2025 | The company announced the departure of Bryan T Baldasare from the board in an SEC filing |
| Oct 14, 2025 | John Steven Bathery became a director |
| Feb 10, 2025 | The company announced the departure of Janet P Grove from the board in an SEC filing |
| Oct 9, 2024 | Neil A Klompas became a director |
| Aug 2, 2024 | Alexandra Diane Janet Mancini reported in an SEC filing no longer being Sr VP, Clinical Reg Affairs |
| Feb 20, 2024 | Netta Jagpal became Chief Financial Officer |
| Dec 12, 2022 | Jonathan Tegge became Interim CFO |
| Nov 16, 2022 | Sarah Li became VP, Accounting and Controller |
| Nov 15, 2022 | Shane Aaron Johnson listed as Sr VP & General Manager (previously SVP, GM of BayMedica LLC) in SEC filings |
| Nov 15, 2022 | Michael Woudenberg listed as Chief Operating Officer (previously VP, Chem/Manufacturing/Control) in SEC filings |
| Aug 9, 2022 | The company announced the departure of Adam D. Cutler from the board in an SEC filing |
| Aug 8, 2022 | Nicole Lemerond became a director |
| May 12, 2022 | Bryan T Baldasare became a director |
| Apr 1, 2022 | Brenda Edwards became Interim CFO |
| Mar 17, 2022 | The company announced the departure of Bruce Colwill as CFO in an SEC filing |
| Feb 11, 2022 | The company announced the departure of Catherine Sazdanoff from the board in an SEC filing |
| Feb 11, 2022 | Janet P Grove became a director |
| Nov 2, 2021 | Shane Aaron Johnson became SVP, GM of BayMedica LLC |
| Dec 18, 2020 | Eric A Adams no longer listed as a 10% owner in SEC filings |
| Nov 12, 2020 | William J Garner became a director |
| Nov 12, 2020 | Michael Woudenberg became VP, Chem/Manufacturing/Control |
| Nov 12, 2020 | Eric C Hsu became Sr. VP, Pre-Clinical Res/Dev |
| Nov 12, 2020 | Eric A Adams became a director |
| Nov 12, 2020 | Eric A Adams became a 10% owner |
| Nov 12, 2020 | Eric A Adams became President & CEO |
| Nov 12, 2020 | Catherine Sazdanoff became a director |
| Nov 12, 2020 | Bruce Colwill became CFO |
| Nov 12, 2020 | Andrew Hull became a director |
| Nov 12, 2020 | Alexandra Diane Janet Mancini became Sr VP, Clinical Reg Affairs |
| Nov 12, 2020 | Adam D. Cutler became a director |
- Prev
- 1
Not reported recently (4)
- Jonathan Tegge · Last reported as Interim CFO in an SEC filing dated Dec 26, 2023
- Sarah Li · Last reported as VP, Accounting and Controller in an SEC filing dated Dec 19, 2022
- Brenda Edwards · Last reported as Interim CFO in an SEC filing dated Apr 8, 2022
- William J Garner · Last reported as a director in an SEC filing dated Jan 24, 2022
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.